Treatment
Adebrelimab clinical trials
We’re tracking 131 recruiting studies that include Adebrelimab, each written for real people, not researchers, below.
Recruiting studies
- NCT06985602RecruitingPhase 2
Adebrelimab with Chemo and Radiation for Stomach Cancer
This trial tests a drug called adebrelimab along with chemotherapy and radiation before surgery for stomach or gastroesophageal junction cancer that has spread locally or has limited spread. It aims to see if this combination can help make the tumor removable and improve outcomes.
Nanjing, ProvinceAges 18–80 - NCT07059221RecruitingPhase 1/Phase 2
New drug combo for advanced head and neck cancer
This trial tests a new combination of drugs (SHR-A2102 and Adebrelimab) with or without other anti-cancer therapies for head and neck cancer that has come back or spread. It aims to see if these treatments can shrink tumors or slow the disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06277791RecruitingPhase 2
Adebrelimab plus chemo before surgery for advanced oral cancer
This trial is testing a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (paclitaxel and carboplatin) given before surgery for advanced oral cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hubei, WuhanAges 18–75 - NCT07007364RecruitingPhase 2
Testing low-dose radiation with immunotherapy and chemo for early oral cancer
This trial tests if combining a low dose of radiation with an immunotherapy drug (adebrelimab) and a chemotherapy drug (albumin-bound paclitaxel) before surgery can help treat early-stage oral squamous cell carcinoma. It aims to see if this combination is safe and effective.
Wuhan, HubeiAges 18–70 - NCT06925516RecruitingPhase 2
Apatinib plus immunotherapy and chemo for unresectable bile duct cancer
This study tests a combination of two drugs (apatinib and adebrelimab) with standard chemotherapy for people with bile duct cancer that cannot be removed surgically. The goal is to see if this combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–75 - NCT06500208RecruitingPhase 2
Adebrelimab plus chemo before surgery for high-risk breast cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06869213RecruitingPhase 2
Adebrelimab plus chemo before and after surgery for esophageal cancer
This trial tests a combination of the immunotherapy drug adebrelimab (SHR-1316) and chemotherapy given before and after surgery for locally advanced esophageal squamous cell carcinoma that can be removed. The goal is to see if this approach helps shrink the tumor and improves outcomes.
BeijingAges 18–75 - NCT06879145RecruitingPhase 2/Phase 3
Study of SHR-A2102 and Adebrelimab for muscle-invasive bladder cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, for people with muscle-invasive bladder cancer that hasn't spread. The goal is to see if this treatment can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06808971RecruitingPhase 2
Perioperative drug combo for advanced stomach cancer
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
BeijingAges 18–75 - NCT06773156Enrolling by invitationPhase 2
Adebrelimab plus apatinib after chemoradiation for limited-stage SCLC
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Nanchang, JiangxiAges 18–75 - NCT06771609RecruitingPhase 2
Immunotherapy plus low-dose chemo for advanced triple-negative breast cancer
This study tests a combination of an immunotherapy drug (PD-L1 inhibitor) with a special low-dose chemotherapy regimen (VEX) plus optional radiation for advanced triple-negative breast cancer. The goal is to see if this approach works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06618664RecruitingPhase 3
New triple combo vs standard therapy for advanced liver cancer
This trial tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard immunotherapy combinations (sintilimab or atezolizumab plus bevacizumab) for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if the new combo works better for shrinking or controlling the cancer.
Hefei, AnhuiAges 18 years+ - NCT06610734RecruitingPhase 2
Combination treatment for extensive-stage small cell lung cancer
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
SichuanAges 18–75 - NCT06584227RecruitingPhase 2
Adebrelimab and Chidamide for advanced pancreatic cancer
This trial tests a combination of two drugs (Adebrelimab and Chidamide) in people with advanced pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT06512051RecruitingPhase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT06483282RecruitingPhase 2
Study of immunotherapy plus targeted therapy and chemo before surgery for lung cancer
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
Hangzhou, ZhejiangAges 18–75 - NCT06427239RecruitingPhase 1/Phase 2
HRS-4642 and adebrelimab for advanced pancreatic cancer
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06433609RecruitingPhase 2
ADC plus immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06350006RecruitingPhase 1
Testing SHR-A1904 combinations for CLDN18.2-positive advanced tumors
This study tests an experimental drug combination for people with advanced solid tumors that have a specific protein called CLDN18.2. It aims to see if the combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06339619RecruitingPhase 2
Combination immunotherapy for advanced esophageal cancer after prior treatment
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Guangzhou, GuangdongAges 18–75 - NCT06091124RecruitingPhase 2
Immunotherapy plus chemo before surgery for neuroendocrine bladder cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT06261125RecruitingPhase 2
SBRT plus immunotherapy and targeted drug for liver cancer
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Guangzhou, GuangdongAges 18–75 - NCT06424899RecruitingPhase 2
Chemoimmunotherapy before and after chemoradiation for stage III lung cancer
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
Hangzhou, ZhejiangAges 18–75
Common questions
- Are there clinical trials studying Adebrelimab?
- Yes. Clin2 currently lists 131 recruiting studies that include Adebrelimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Adebrelimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Adebrelimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Adebrelimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.